N
TERN

Nuveen’s Terns Pharmaceuticals TERN Stock Holding History

Nuveen’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.7M Sell
772,592
-305,565
-28% -$12.6M 0.01% 745
2025
Q4 		$43.6M Sell
1,078,157
-395,214
-27% -$9.13M 0.01% 713
2025
Q3 		$11.1M Buy
1,473,371
+292,843
+25% +$1.87M ﹤0.01% 1489
2025
Q2 		$4.4M Sell
1,180,528
-225,373
-16% -$704K ﹤0.01% 1941
2025
Q1 		$3.88M Sell
1,405,901
-1,228,017
-47% -$5.01M ﹤0.01% 2047
2024
Q4 		$14.6M Buy
2,633,918
+617,009
+31% +$4.18M ﹤0.01% 1368
2024
Q3 		$16.8M Buy
2,016,909
+1,269,467
+170% +$10.4M ﹤0.01% 1301
2024
Q2 		$5.09M Buy
747,442
+587,870
+368% +$3.56M ﹤0.01% 1945
2024
Q1 		$1.05M Buy
159,572
+2,940
+2% +$19.2K ﹤0.01% 2689
2023
Q4 		$1.02M Buy
156,632
+37,952
+32% +$201K ﹤0.01% 2729
2023
Q3 		$597K Sell
118,680
-57,458
-33% -$365K ﹤0.01% 2784
2023
Q2 		$1.54M Buy
+176,138
New +$2.05M ﹤0.01% 2474
2022
Q2 		– Sell
-14,237
Closed -$43K – 3474
2022
Q1 		$43K Hold
14,237
– – ﹤0.01% 3280
2021
Q4 		$83K Hold
14,237
– – ﹤0.01% 3289
2021
Q3 		$150K Hold
14,237
– – ﹤0.01% 3297
2021
Q2 		$175K Buy
14,237
+152
+1% +$2.59K ﹤0.01% 3257
2021
Q1 		$310K Buy
+14,085
New +$309K ﹤0.01% 3166

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Nuveen's TERN Position: Q1 2026 in Review

Nuveen reduced its Terns Pharmaceuticals (TERN) stake by 28% in Q1 2026, selling an estimated $12.6M and leaving 772,592 shares worth $40.7M. The position accounts for 0.01% of the portfolio, ranked #745.

Nuveen first reported a position in TERN in Q1 2021 and has held it in 17 quarters since. The position peaked at $43.6M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Nuveen held 772,592 shares of Terns Pharmaceuticals worth $40.7M as of Q1 2026.
  • Nuveen sold 305,565 Terns Pharmaceuticals shares in Q1 2026, an estimated $12.6M.
  • Terns Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q1 2026, its #745 holding.
  • Nuveen first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
  • Nuveen's Terns Pharmaceuticals position peaked at $43.6M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.